|
Volumn 11, Issue 5, 2015, Pages 262-264
|
Connective tissue diseases: SLE classification: Plus ça change, plus c'est la même chose
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINUCLEAR ANTIBODY;
DOUBLE STRANDED DNA ANTIBODY;
HYDROXYCHLOROQUINE;
BELIMUMAB;
BIOLOGICAL MARKER;
IMMUNOSUPPRESSIVE AGENT;
MONOCLONAL ANTIBODY;
ARTHROPLASTY;
AVASCULAR NECROSIS;
CORTICOSTEROID INDUCED OSTEOPOROSIS;
COST;
CROSS-SECTIONAL STUDY;
DISEASE CLASSIFICATION;
DISEASE EXACERBATION;
ECHOGRAPHY;
HUMAN;
KIDNEY TRANSPLANTATION;
MEDICAL RESEARCH;
MORBIDITY;
MORTALITY;
OBSERVATIONAL STUDY;
OPPORTUNISTIC INFECTION;
PORTUGAL;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEOMICS;
RENAL REPLACEMENT THERAPY;
SENSITIVITY AND SPECIFICITY;
SHORT SURVEY;
SPAIN;
STANDARDIZATION;
SYSTEMIC LUPUS ERYTHEMATOSUS;
TREATMENT INDICATION;
CLASSIFICATION;
DISEASE MANAGEMENT;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
METABOLISM;
ANTIBODIES, MONOCLONAL, HUMANIZED;
BIOMARKERS;
CROSS-SECTIONAL STUDIES;
DISEASE MANAGEMENT;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
SENSITIVITY AND SPECIFICITY;
|
EID: 84929030530
PISSN: 17594790
EISSN: 17594804
Source Type: Journal
DOI: 10.1038/nrrheum.2015.16 Document Type: Short Survey |
Times cited : (3)
|
References (7)
|